-

ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials

ZAMUDIO, Spain--(BUSINESS WIRE)--ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP.

The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnológico y la Innovación. This endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to treat metastatic solid tumors.

“We are thrilled to count on the continued support of our existing investors and welcome CDTI through Innvierte, an investment program of CDTI” said Dr. Laureano Simon, CEO of ONCOMATRYX. “This funding validates our clinical progress and equips us to execute on critical milestones and deliver transformative therapies to patients.”

About Oncomatryx

Oncomatryx has developed a proprietary Antibody-Drug Conjugates platform that targets Cancer-Associated Fibroblasts in the microenvironment of metastatic solid tumors.

Oncomatryx pioneering ADCs against immunosuppressive CAFs are developed in collaboration with prestigious universities, hospitals and research centers in USA and Europe.

Phase I clinical results of OMTX705, a novel ADC targeting Fibroblast Activation Protein in the Cancer-Associated Fibroblasts, will be presented at major Oncology conferences along 2025.

https://clinicaltrials.gov/ct2/show/NCT05547321?term=oncomatryx&draw=2&rank=1

For more information and updates about Oncomatryx and its clinical programs, please contact:

Contacts

Pedro Esnaola
CPAO
pesnaola@oncomatryx.com

Industry:

ONCOMATRYX BIOPHARMA, S.L.

Release Versions
English

Contacts

Pedro Esnaola
CPAO
pesnaola@oncomatryx.com

More News From ONCOMATRYX BIOPHARMA, S.L.

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment

ZAMUDIO, Spain--(BUSINESS WIRE)--Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates...

Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors

BILBAO, Spain--(BUSINESS WIRE)--After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance a...

Oncomatryx Announces a €15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment

BILBAO, Spain--(BUSINESS WIRE)--Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment - targeted ADCs. OMTX705, the Crown Jewel, has already proven high antitumor efficacy and unbeatable ADC safety in murine and non-human primate models. Phase I clinical trials in patients suffering metastatic solid tumors will be launched in Europe and USA in Q2 2022. In order to fund OMTX705 Phase I clinical trials, Oncoma...
Back to Newsroom